Epidermal Growth Factor Receptor – Ras homolog enriched in brain guanine nucleotide exchange factor interface (EGFR–Rheb interface)

The Epidermal Growth Factor Receptor (EGFR) – Rheb-GEF interface is a non-canonical signaling site where the kinase domain of EGFR functions directly as a Guanine Nucleotide Exchange Factor (GEF) for the small GTPase Rheb. This interaction facilitates the conversion of Rheb-GDP to its active Rheb-GTP form, which is the primary activator of the Mechanistic Target of Rapamycin Complex 1 (mTORC1). Unlike the classical pathway where EGFR activates mTORC1 via the PI3K/Akt/TSC axis, this direct interface allows for Akt-independent mTORC1 signaling, providing a critical survival and growth mechanism in various malignancies. In the context of disease, this interface is highly relevant to cancers that exhibit resistance to traditional EGFR tyrosine kinase inhibitors (TKIs), as the GEF activity may persist or be bypassed through specific protein-protein interactions. Research indicates that targeting this specific interface, rather than just the catalytic kinase activity, could overcome resistance in non-small cell lung cancer and glioblastoma. While current FDA-approved EGFR inhibitors primarily target the ATP-binding pocket of the kinase domain, they may indirectly modulate this interface; however, the development of specific protein-protein interaction (PPI) inhibitors is an emerging area of therapeutic interest. Understanding this interface provides a more comprehensive view of how EGFR drives oncogenic growth and offers a novel target for precision oncology.

Other names

EGFR-Rheb complexEGFR-Rheb interaction siteEGFR-Rheb GEF interfaceEpidermal Growth Factor Receptor – Rheb interface

Inhibition of the direct guanine nucleotide exchange factor (GEF) activity of the EGFR kinase domain toward Rheb, thereby preventing the loading of Rheb with GTP and subsequent activation of the mTORC1 pathway.